Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group

In the post-rituximab era, patients with relapsed/refractory non-Hodgkin B-cell lymphoma (R/R B-NHL) responding to a platinum salt-based salvage regimen can potentially be cured after intensification followed by autologous stem cell transplantation, with the quality of the response to salvage predic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers
Main Authors: Christophe Bonnet, Jehan Dupuis, Hervé Tilly, Thierry Lamy, Christophe Fruchart, Steven le Gouill, Catherine Thieblemont, Franck Morschhauser, Olivier Casasnovas, Krimo Bouabdallah, Hervé Ghesquieres, Eric Van Den Neste, Marc André, Guillaume Cartron, Gilles Salles
Formato: Artigo
Publicado em: MDPI AG 2022-03-01
Assuntos:
Relapsed/refractory non-Hodgkin B-cell lymphoma
Ibrutinib
R-DHAP
R-DHAOx
Safety
Acesso em linha:https://www.mdpi.com/2072-6694/14/7/1761
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://www.mdpi.com/2072-6694/14/7/1761

Registos relacionados